A post hoc analysis of the phase 2 FILLY study demonstrated that patients who received multiple intravitreal injections of pegcetacoplan had a lower rate of progression from nascent geographic atrophy to GA as compared with sham.
“We were able to demonstrate that complement C3 inhibitor pegcetacoplan impacts the progression of nascent geographic atrophy, providing evidence to further explore the potential for an earlier intervention,” SriniVas Sadda, MD, said at the virtual Euretina congress.
Most therapeutic trials, such as FILLY, focus on the end stage of GA, trying to prevent
Uncategorized